Table 1.

Pathways enriched with common variation associated with schizophrenia with putative clinical actionability.

Pathway	P threshold (PT)	P value
NOS1 pathway	All SNPs	6.3 × 10−4
Regulation of insulin secretion	P < 0.5	3.9 × 10−4
CRMPs in Sema3A signalling	P < 0.5	9.4 × 10−4
GABA synthesis, release, reuptake and degradation	P < 0.5	5.8 × 10−4
One carbon pool by folate	P < 0.05	1.4 × 10−4
Hedgehog signalling	P < 0.05	1.9 × 10−4
HIF-2 pathway	P < 0.005	3.1 × 10−5
Acetylcholine binding and downstream events	P < 0.005	3.8 × 10−4

Pathways with putative clinical actionability by virtue of having targets for existing drugs with potential for repurposing. The P thresholds denote the SNPs included in the model, that is, only SNPs below that threshold of association in the GWAS were included. P values refer gene-set association of aggregated SNPs for this pathway from the schizophrenia in the PGC GWAS.